Supernus Pharmaceuticals, Inc.
- SUPN
- NASDAQ
- Drug Manufacturers - Specialty & Generic
- CNS Therapies
- Neurology Pharmaceuticals
$37.88
Today −4.27%Quote Oct 16, 2026, 08:00 PM UTC
−11.74%over the last month
Max drawdown −15.1%From 1-month high −15.1%3 months −20.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$2.21B
Quote Oct 16
Next earnings
Nov 3
Expected, not confirmed
Analyst target
$57.60
+52.1% from here
Floor
$34.44
9.1% below price
Where the price sits
14 analysts
Analyst range, low to high
$40.00$65.00
- Price $37.88
- Resistance $39.13
- Consensus $57.60
Analysts' average target sits about 52% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SUPNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $371.2M
- Product$165.7M44.6%
- Qelbree$89.2M24.0%
- GOCOVRI$37.5M10.1%
- Collaboration Revenue$35.4M9.5%
- Royalty, License And Other Revenue$18.0M4.8%
- Oxtellar X R$8.8M2.4%
- Trokendi Xr$8.4M2.3%
- APOKYN$6.3M1.7%
- Manufactured Product, Other$1.9M0.5%
Industry
Drug Manufacturers - Specialty & Generic
Employees
778